Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 18,99€ (+34,87%). La mediana è 17,59€ (+24,93%).
| Acquista |
10 |
| Mantieni |
2 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » Altro su finance.yahoo.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 0,00 | - |
| Utile lordo | 0,00 | - |
| Utile netto | −29,88M | 31,30% |
| EBITDA | −29,79M | 31,13% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 191,93M€ |
Numero di azioni | 13,62M |
Massimo/minimo a 52 settimane | 14,96€ - 4,34€ |
| Dividendi | No |
Beta | 1,4 |
Rapporto P/E | −3,42 |
Rapporto PEG | −0,04 |
Rapporto P/B | 5,47 |
Rapporto P/S | 0,00 |
Profilo aziendale
| Nome | Immunic |
| CEO | Erik Lundgren |
| Dipendenti | 95 |
Scopri gli asset
Gli azionisti di Immunic investono anche nei seguenti asset
